{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:24:32Z","timestamp":1790540672836,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014841","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000}}],"reference-count":106,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014841.pub2","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:14:27Z","timestamp":1652872467000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin"],"prefix":"10.1002","volume":"2022","author":[{"given":"Samantha","family":"Pillay","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R","family":"Steingart","sequence":"additional","affiliation":[{"name":"Honorary Research Fellow; Department of Clinical Sciences, Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraint R","family":"Davies","sequence":"additional","affiliation":[{"name":"Institute of Infection, Veterinary and Ecological Sciences; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty","family":"Chaplin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretha","family":"De Vos","sequence":"additional","affiliation":[{"name":"FIND; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G","family":"Schumacher","sequence":"additional","affiliation":[{"name":"FIND; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Warren","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Theron","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences; Stellenbosch University; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"10.1002\/14651858.CD014841.pub2-BIB0001|cit1","unstructured":"Omar S Shining a new light on TB diagnostics: clinical evaluation of the Xpert\u00ae MTB\/XDR assay 51st Union World Conference on Lung Health, virtual conference"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0002|cit2","unstructured":"Omar S Shining a new light on TB diagnostics: clinical evaluation of the Xpert\u00ae MTB\/XDR assay 51st Union World Conference on Lung Health, virtual conference"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0003|cit3","unstructured":"Omar S Ismail N Shining a new light on TB diagnostics: clinical evaluation of the Xpert\u00ae MTB\/XDR assay 51st Union World Conference on Lung Health, virtual conference"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Penn-Nicholson A Georghiou SB Ciobanu N Kazi M Bhalla M David A Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study Lancet Infectious Diseases 2021 Oct 7 [Epub ahead of print] 10.1016\/S1473-3099(21)00452-7","DOI":"10.1016\/S1473-3099(21)00452-7"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Penn-Nicholson A Georghiou SB Ciobanu N Kazi M Bhalla M David A Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study Lancet Infectious Diseases 2021 Oct 7 [Epub ahead of print] 10.1016\/S1473-3099(21)00452-7","DOI":"10.1016\/S1473-3099(21)00452-7"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Penn-Nicholson A Georghiou SB Ciobanu N Kazi M Bhalla M David A Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study Lancet Infectious Diseases 2021 Oct 7 [Epub ahead of print] 10.1016\/S1473-3099(21)00452-7","DOI":"10.1016\/S1473-3099(21)00452-7"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Penn-Nicholson A Georghiou SB Ciobanu N Kazi M Bhalla M David A Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study Lancet Infectious Diseases 2021 Oct 7 [Epub ahead of print] 10.1016\/S1473-3099(21)00452-7","DOI":"10.1016\/S1473-3099(21)00452-7"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Penn-Nicholson A Georghiou SB Ciobanu N Kazi M Bhalla M David A Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study Lancet Infectious Diseases 2021 Oct 7 [Epub ahead of print] 10.1016\/S1473-3099(21)00452-7","DOI":"10.1016\/S1473-3099(21)00452-7"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.24075\/brsmu.2020.001","article-title":"Isoniazid-resistant Mycobacterium tuberculosis: prevalence, resistance spectrum and genetic determinants of resistance","volume":"1","author":"Andreevskaya","year":"2020","journal-title":"Bulletin of Russian State Medical University"},{"issue":"1","key":"10.1002\/14651858.CD014841.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"e0227215","DOI":"10.1371\/journal.pone.0227215","article-title":"A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB\/Rif Ultra and FluoroType MTB","volume":"15","author":"Beutler","year":"2020","journal-title":"PLOS One"},{"issue":"5","key":"10.1002\/14651858.CD014841.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"e0232632","DOI":"10.1371\/journal.pone.0232632","article-title":"Simultaneous detection of Mycobacterium tuberculosis complex and resistance to rifampicin and isoniazid by MDR\/MTB ELITe MGB R kit for the diagnosis of tuberculosis","volume":"15","author":"Bisognin","year":"2020","journal-title":"PLOS One"},{"issue":"7","key":"10.1002\/14651858.CD014841.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10096-018-3246-2","article-title":"Experimental platform utilising melting curve technology for detection of mutations in Mycobacterium tuberculosis isolates","volume":"37","author":"Broda","year":"2018","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD014841.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"e02314","DOI":"10.1128\/JCM.02314-20","article-title":"Xpert MTB\/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, fluoroquinolone, and second-line-injectable-drug resistance directly from Mycobacterium tuberculosis-positive sputum","volume":"59","author":"Cao","year":"2021","journal-title":"Journal of Clinical Microbiology"},{"issue":"1","key":"10.1002\/14651858.CD014841.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/JCM.01771-16","article-title":"Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use","volume":"55","author":"Chakravorty","year":"2017","journal-title":"Journal of Clinical Microbiology"},{"issue":"2","key":"10.1002\/14651858.CD014841.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3343\/alm.2020.40.2.142","article-title":"Evaluation of the QuantaMatrix multiplexed assay platform for molecular diagnosis of multidrug- and extensively drug-resistant tuberculosis using clinical strains isolated in Myanmar","volume":"40","author":"Chang","year":"2020","journal-title":"Annals of Laboratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014841.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s11033-020-05331-8","article-title":"Evaluation of Anyplex TM II MTB\/MDR kit's performance to rapidly detect isoniazid and rifampicin resistant Mycobacterium tuberculosis from various clinical specimens","volume":"47","author":"Chumpa","year":"2020","journal-title":"Molecular Biology Reports"},{"issue":"7","key":"10.1002\/14651858.CD014841.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1321-7","DOI":"10.1007\/s10096-020-03847-2","article-title":"Evaluation of the BD MAX TM MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB","volume":"39","author":"Ciesielczuk","year":"2020","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD014841.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.5588\/ijtld.15.0896","article-title":"Comparison of TaqMan( R) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB","volume":"20","author":"Foongladda","year":"2016","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12879-016-1615-y","article-title":"High-resolution melting analysis for molecular detection of multidrug resistance tuberculosis in Peruvian isolates","volume":"16","author":"Galarza","year":"2016","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD014841.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"115397","DOI":"10.1016\/j.diagmicrobio.2021.115397","article-title":"Analytical performance of the Xpert MTB\/XDR R assay for tuberculosis and expanded resistance detection","volume":"101","author":"Georghiou","year":"2021","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"issue":"12","key":"10.1002\/14651858.CD014841.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2174\/1389201020666190716104131","article-title":"The application of Xpert Mycobacterium tuberculosis\/rifampicin, quantitative polymerase chain reaction and high resolution melting curve in the diagnosis of superficial lymph node TB","volume":"20","author":"Han","year":"2019","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"2","key":"10.1002\/14651858.CD014841.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e01249","DOI":"10.1128\/JCM.01249-17","article-title":"Rapid microarray-based detection of rifampin, isoniazid, and fluoroquinolone resistance in Mycobacterium tuberculosis by use of a single cartridge","volume":"56","author":"Havlicek","year":"2018","journal-title":"Journal of Clinical Microbiology"},{"issue":"9","key":"10.1002\/14651858.CD014841.pub2-BIB0023|cit23","first-page":"680","article-title":"[A study of the value of three molecular diagnostic techniques in the diagnosis of tuberculosis]","volume":"38","author":"Huang","year":"2015","journal-title":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3389\/fmicb.2019.01075","article-title":"Comparison of Quantamatrix multiplexed assay platform and GenoType MTBDR assay using smear-positive sputum specimens from patients with multidrug-resistant\/extensively drug-resistant tuberculosis in South Korea","volume":"10","author":"Kim","year":"2019","journal-title":"Frontiers in Microbiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mimet.2018.06.003","article-title":"TB-EFI, a novel 18-Plex microbead-based method for prediction of second-line drugs and ethambutol resistance in Mycobacterium tuberculosis complex","volume":"152","author":"Klotoe","year":"2018","journal-title":"Journal of Microbiological Methods"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ab.2017.12.031","article-title":"Automated real-time detection of drug-resistant Mycobacterium tuberculosis on a lab-on-a-disc by recombinase polymerase amplification","volume":"544","author":"Law","year":"2018","journal-title":"Analytical Biochemistry"},{"issue":"5","key":"10.1002\/14651858.CD014841.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jiac.2014.12.009","article-title":"Performance of REBA MTB-XDR to detect extensively drug-resistant tuberculosis in an intermediate-burden country","volume":"21","author":"Lee","year":"2015","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tube.2017.03.008","article-title":"A novel automatic molecular test for detection of multidrug resistance tuberculosis in sputum specimen: a case control study","volume":"105","author":"Li","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"10.1002\/14651858.CD014841.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1128\/JCM.00537-19","article-title":"GeneXpert MTB\/RIF is superior to BBD Max MDR-TB for diagnosis of tuberculosis (TB) in a country with low incidence of multidrug-resistant TB (MDR-TB)","volume":"57","author":"Mokaddas","year":"2019","journal-title":"Journal of Clinical Microbiology"},{"issue":"9","key":"10.1002\/14651858.CD014841.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"e00779","DOI":"10.1128\/JCM.00779-19","article-title":"Comparative performance of BD MAX MDR-TB and Cepheid Xpert MTB\/RIF assays","volume":"57","author":"Murray","year":"2019","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"25330","DOI":"10.1038\/srep25330","article-title":"Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China","volume":"6","author":"Pang","year":"2016","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1002\/14651858.CD014841.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1590\/0074-02760160376","article-title":"Detection of tuberculosis drug resistance: a comparison by Mycobacterium tuberculosis MLPA assay versus Genotype\u00aeMTBDRplus","volume":"112","author":"Santos","year":"2017","journal-title":"Memorias do Instituto Oswaldo Cruz"},{"issue":"5","key":"10.1002\/14651858.CD014841.pub2-BIB0033|cit33","first-page":"ciz932","article-title":"Multicenter study of the accuracy of the BD MAX\u2122 MDR-TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid","volume":"71","author":"Shah","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD014841.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/JCM.01691-15","article-title":"Comparison of three commercial molecular assays for detection of rifampin and isoniazid resistance among Mycobacterium tuberculosis isolates in a High-HIV-prevalence setting","volume":"53","author":"Strydom","year":"2015","journal-title":"Journal of Clinical Microbiology"},{"issue":"6","key":"10.1002\/14651858.CD014841.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3343\/alm.2018.38.6.569","article-title":"Detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis using the Quantamatrix multiplexed assay platform system","volume":"38","author":"Wang","year":"2018","journal-title":"Annals of Laboratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014841.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJMoa1614915","article-title":"Evaluation of a rapid molecular drug-susceptibility test for tuberculosis","volume":"377","author":"Xie","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0037|cit37","unstructured":"DIAgnostics for Multidrug Resistant Tuberculosis in Africa (DIAMA) clinicaltrials.gov\/ct2\/show\/NCT03303963"},{"issue":"4","key":"10.1002\/14651858.CD014841.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD014841.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.01053-10","article-title":"Containment of bioaerosol infection risk by the Xpert MTB\/RIF assay and its applicability to point-of-care settings","volume":"48","author":"Banada","year":"2010","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0040|cit40","unstructured":"Bisimwa BC Nachega JB Warren RM Theron G Metcalfe JZ Shah M Xpert MTB\/RIF-detected rifampicin resistance is a sub-optimal surrogate for multidrug resistant tuberculosis in Eastern Democratic Republic of the Congo: diagnostic and clinical implications Clinical Infectious Diseases ciaa873 10.1093\/cid\/ciaa873"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0041|cit41","unstructured":"Pipeline report 2021 tuberculosis diagnostics www.treatmentactiongroup.org\/wp-content\/uploads\/2021\/11\/pipeline_TB_diagnostics_2021_final.pdf?eType=EmailBlastContent&eId=be63ab55-6126-410b-9861-a2d936dec603"},{"issue":"1","key":"10.1002\/14651858.CD014841.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1128\/AAC.01030-10","article-title":"Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis","volume":"55","author":"Brossier","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0043|cit43","unstructured":"Xpert\u00ae MTB\/XDR. GXMTB\/XDR-10 www.cepheid.com\/Package%20Insert%20Files\/Xpert%20MTB-XDR%20ENGLISH%20Package%20Insert%20302-3514%20Rev%20C.pdf"},{"issue":"8","key":"10.1002\/14651858.CD014841.pub2-BIB0044|cit44","first-page":"1024","article-title":"Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting","volume":"14","author":"Chihota","year":"2010","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"6","key":"10.1002\/14651858.CD014841.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2174\/1871526520666200102110235","article-title":"A comprehensive review on DNA gyrase inhibitors","volume":"20","author":"Chitra","year":"2020","journal-title":"Infectious Disorders Drug Targets"},{"issue":"12","key":"10.1002\/14651858.CD014841.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jclinepi.2006.06.011","article-title":"Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach","volume":"59","author":"Chu","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"13","key":"10.1002\/14651858.CD014841.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMe1902904","article-title":"A short regimen for rifampin-resistant tuberculosis","volume":"380","author":"Churchyard","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD014841.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0049|cit49","unstructured":"Conradie F High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid [Conference presentation]. International AIDS Society, Berlin, Germany https:\/\/theprogramme.ias2021.org\/Abstract\/Abstract\/2405 (accessed 6 March 2022)"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0050|cit50","unstructured":"Veritas Health Innovation Covidence"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0051|cit51","unstructured":"Curry International Tuberculosis Center and California Department of Public Health Drug-resistant tuberculosis: a survival guide for clinicians, third edition, 2016 www.currytbcenter.ucsf.edu\/products\/cover-pages\/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition"},{"issue":"18","key":"10.1002\/14651858.CD014841.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014841.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014877.pub2","article-title":"Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views","author":"Engel","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD014841.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/jama.283.19.2537","article-title":"Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries","volume":"283","author":"Espinal","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD014841.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1093\/cid\/ciaa1402","article-title":"Subclinical tuberculosis disease-a review and analysis of prevalence surveys to Inform definitions, burden, associations, and screening methodology","volume":"73","author":"Frascella","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0056|cit56","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2020"},{"issue":"1","key":"10.1002\/14651858.CD014841.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1186\/s13063-021-05491-3","article-title":"Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial","volume":"22","author":"Guglielmetti","year":"2021","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD014841.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e01550","DOI":"10.1128\/AAC.01550-17","article-title":"What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi-and extensively drug-resistant tuberculosis","volume":"62","author":"Heyckendorf","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD014841.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw694","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD014841.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jinf.2019.08.004","article-title":"Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: a meta-analysis of findings","volume":"79","author":"Liu","year":"2019","journal-title":"Journal of Infection"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmjebm-2019-111230","article-title":"What to do with a clinical trial with conflicts of interest","volume":"25","author":"Lundh","year":"2020","journal-title":"BMJ Evidence-based Medicine"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0062|cit62","unstructured":"Macaskill P Gatsonis C Deeks JJ Harbord RM Takwoingi Y Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010 Available from: http:\/\/srdta.cochrane.org\/"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0063|cit63","unstructured":"TB PRACTECAL: MSF clinical trial finds short, effective and safe drug-resistant tuberculosis treatment https:\/\/msf.org.uk\/article\/tb-practecal-msf-clinical-trial-finds-short-effective-and-safe-drug-resistant-tuberculosis"},{"issue":"4","key":"10.1002\/14651858.CD014841.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(19)30370-4","article-title":"Xpert MTB\/RIF Ultra and Xpert MTB\/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study","volume":"8","author":"Mishra","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014841.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10096-017-3079-4","article-title":"The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran","volume":"37","author":"Nasiri","year":"2018","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0066|cit66","unstructured":"NIH National Human Genome Research Institute Talking glossary of genomic and genetic terms www.genome.gov\/glossary\/"},{"issue":"8","key":"10.1002\/14651858.CD014841.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0068|cit68","unstructured":"National Institute for Communicable Diseases South African tuberculosis drug resistance survey 2012-14, 2016 nicd.ac.za\/assets\/files\/K-12750%20NICD%20National%20Survey%20Report_Dev_V11-LR.pdf"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0069|cit69","unstructured":"O'Neill J Tackling drug-resistant infections globally: final report and recommendations (UK Review on Antimicrobial Resistance) 2016 amr-review.org\/sites\/default\/files\/160518_Final%20paper_with%20cover.pdf"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1371\/journal.pmed1000097","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nature Review Disease Primers"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp2118145","article-title":"Covid-19\u2019s devastating effect on tuberculosis care - a path to recovery","volume":"Jan 5","author":"Pai","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD014841.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0074|cit74","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2020"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Rutjes AW Reitsma JB Vandenbroucke JP Glas AS Bossuyt PM Case-control and two-gate designs in diagnostic accuracy studies Clinical Chemistry 2005 51 8 1335 41 10.3310\/hta11500","DOI":"10.1373\/clinchem.2005.048595"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"m2632","DOI":"10.1136\/bmj.m2632","article-title":"Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist","volume":"370","author":"Salameh","year":"2020","journal-title":"BMJ"},{"issue":"7653","key":"10.1002\/14651858.CD014841.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","article-title":"GRADE guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy","volume":"122","author":"Sch\u00fcnemann","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","article-title":"GRADE guidelines: 21 part 2. Inconsistency, imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables","volume":"122","author":"Sch\u00fcnemann","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"f2778","DOI":"10.1136\/bmj.f2778","article-title":"Diagnostic accuracy studies: how to report and analyse inconclusive test results","volume":"346","author":"Shinkins","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0082|cit82","unstructured":"Stata Statistical Software Release 16 StataCorp 2019"},{"issue":"7","key":"10.1002\/14651858.CD014841.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"544","DOI":"10.7326\/0003-4819-158-7-201304020-00006","article-title":"Empirical evidence of the importance of comparative studies of diagnostic test accuracy","volume":"158","author":"Takwoingi","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014841.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1177\/0962280215592269","article-title":"Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data","volume":"26","author":"Takwoingi","year":"2017","journal-title":"Statistical Methods in Medical Research"},{"issue":"8","key":"10.1002\/14651858.CD014841.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/cid\/civ1223","article-title":"Xpert MTB\/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results?","volume":"62","author":"Theron","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD014841.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010705.pub3","article-title":"GenoType\u00ae MTBDRsl assay for resistance to second-line anti-tuberculosis drugs","author":"Theron","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0087|cit87","unstructured":"Transforming our world: the 2030 agenda for sustainable development. Resolution adopted by the General Assembly on 25 September 2015 sustainabledevelopment.un.org\/post2015\/transformingourworld"},{"issue":"8","key":"10.1002\/14651858.CD014841.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0089|cit89","unstructured":"World Health Organization Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO www.who.int\/publications\/i\/item\/9789240028173"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0090|cit90","unstructured":"World Health Organization WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Licence: CC BY-NC-SA 3.0 IGO who.int\/publications\/i\/item\/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0091|cit91","unstructured":"World Health Organization WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, June 2020 who.int\/publications\/i\/item\/9789240007048"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0092|cit92","unstructured":"World Health Organization Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. (WHO\/CDS\/TB\/2018.5). Licence: CC BY-NC-SA 3.0 IGO https:\/\/apps.who.int\/iris\/handle\/10665\/260470"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0093|cit93","unstructured":"World Health Organization Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine) (WHO\/CDS\/TB\/2018.5). NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/igo) who.int\/publications\/i\/item\/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine)"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0094|cit94","unstructured":"World Health Organization Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014 and January 2020) https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/79199\/9789241505345_eng.pdf"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0095|cit95","unstructured":"World Health Organization The END TB strategy, 2015 apps.who.int\/iris\/bitstream\/handle\/10665\/331326\/WHO-HTM-TB-2015.19-eng.pdf"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0096|cit96","unstructured":"World Health Organization Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020; CC BY-NC-SA 3.0 IGO who.int\/publications\/i\/item\/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0097|cit97","unstructured":"World Health Organization Global tuberculosis report 2020 who.int\/tb\/publications\/global_report\/en\/"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0098|cit98","unstructured":"World Health Organization Global tuberculosis report 2021 www.who.int\/publications\/digital\/global-tuberculosis-report-2021"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0099|cit99","unstructured":"World Health Organization WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detention, 2021 update. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO www.who.int\/publications\/i\/item\/9789240030589"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0100|cit100","unstructured":"World Health Organization Treatment of drug-susceptible tuberculosis: rapid communication. June 2021 who.int\/publications\/i\/item\/9789240028678"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0101|cit101","unstructured":"World Health Organization Rapid communication: key changes to the treatment of drug-resistant tuberculosis. May 2022 who.int\/publications\/i\/item\/WHO-UCN-TB-2022-2"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0102|cit102","unstructured":"World Health Organization 2021 Target product profile for next-generation drug-susceptibility testing at peripheral centres www.who.int\/publications\/i\/item\/9789240032361"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0103|cit103","unstructured":"World Bank List of Economies datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"10.1002\/14651858.CD014841.pub2-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults Cochrane Database of Systematic Reviews 2021 2 10.1002\/14651858.CD009593.pub4","DOI":"10.1002\/14651858.CD013694.pub2"},{"issue":"10","key":"10.1002\/14651858.CD014841.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014841.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014841","article-title":"Xpert MTB\/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin","author":"Pillay","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T06:03:48Z","timestamp":1665986628000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014841.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014841.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}